Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Neuro Devices Panel Examines Suicide Risk In Depression Trial Subjects

This article was originally published in The Gray Sheet

Executive Summary

Clinical trials of devices for depression do not readily lend themselves to hard-and-fast rules on when the rate of patient suicides might require a trial to be halted, according to FDA’s neurological devices panel.

You may also be interested in...



FDA Panel To Look At Controversial Electroshock Device Classification

FDA's neurological devices advisory panel will meet in January to discuss the possible reclassification of devices used in electroconvulsive therapy.

FDA Panel To Look At Controversial Electroshock Device Classification

FDA's neurological devices advisory panel will meet in January to discuss the possible reclassification of devices used in electroconvulsive therapy.

Neuronetics' NeuroStar Depression Therapy Not Backed By Data - Blues

Existing evidence does not support the long-term efficacy of Neuronetics' NeuroStar transcranial magnetic stimulation therapy for drug-resistant depression, according to a recent 1assessment by the Blue Cross and Blue Shield Association Technology Evaluation Center

Related Content

Topics

UsernamePublicRestriction

Register

MT029496

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel